Mesirow Financial Investment Management Inc. Takes $222,000 Position in Boston Scientific Co. (NYSE:BSX)

Mesirow Financial Investment Management Inc. acquired a new position in Boston Scientific Co. (NYSE:BSX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,655 shares of the medical equipment provider’s stock, valued at approximately $222,000.

Several other large investors have also recently bought and sold shares of the company. GSG Advisors LLC raised its position in shares of Boston Scientific by 4.3% during the third quarter. GSG Advisors LLC now owns 4,888 shares of the medical equipment provider’s stock worth $411,000 after acquiring an additional 200 shares during the last quarter. Essex Savings Bank raised its holdings in Boston Scientific by 36.8% during the 3rd quarter. Essex Savings Bank now owns 3,638 shares of the medical equipment provider’s stock worth $305,000 after purchasing an additional 978 shares during the last quarter. Assetmark Inc. lifted its position in Boston Scientific by 12.5% during the 3rd quarter. Assetmark Inc. now owns 152,810 shares of the medical equipment provider’s stock valued at $12,806,000 after purchasing an additional 16,986 shares during the period. Verdence Capital Advisors LLC boosted its stake in shares of Boston Scientific by 4.3% in the 3rd quarter. Verdence Capital Advisors LLC now owns 4,007 shares of the medical equipment provider’s stock valued at $336,000 after purchasing an additional 165 shares during the last quarter. Finally, Holistic Planning LLC acquired a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $213,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $88.72 on Wednesday. The firm has a market cap of $130.76 billion, a PE ratio of 73.32, a P/E/G ratio of 2.60 and a beta of 0.79. Boston Scientific Co. has a 12 month low of $52.99 and a 12 month high of $89.00. The company’s fifty day simple moving average is $84.74 and its 200-day simple moving average is $79.15. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter last year, the company earned $0.50 EPS. Boston Scientific’s revenue for the quarter was up 19.3% compared to the same quarter last year. Equities research analysts expect that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BSX shares. BTIG Research raised their price objective on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Barclays upped their price objective on Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, August 22nd. Stifel Nicolaus raised their target price on Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, October 18th. JPMorgan Chase & Co. boosted their target price on Boston Scientific from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, July 25th. Finally, Royal Bank of Canada lifted their price objective on shares of Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.39.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the transaction, the chief executive officer now owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total value of $585,594.38. Following the transaction, the executive vice president now directly owns 34,748 shares in the company, valued at $2,913,967.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the sale, the chief executive officer now directly owns 1,572,096 shares of the company’s stock, valued at $133,046,484.48. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 309,270 shares of company stock valued at $26,196,718 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.